<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075412</url>
  </required_header>
  <id_info>
    <org_study_id>200906786</org_study_id>
    <nct_id>NCT01075412</nct_id>
  </id_info>
  <brief_title>FLT PET Imaging for Cervical Cancer</brief_title>
  <official_title>`F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary hypothesis is that [18F]FLT PET can identify active bone marrow in addition to
      metabolically active tumor.

      This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis. The
      radiation plan is then designed to spare that area, in hopes of keeping the bone marrow
      active during therapy. Bone marrow and tumor activity will be monitored using a sequence of
      FLT PET scans during the course of chemotherapy and radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo a total of 5 FLT PET scans.

      Group 1 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation
      treatments, after 15 radiation treatments, and then 1 month after completing radiation
      therapy.

      Group 2 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation
      treatments, after 20 radiation treatments, and then 1 month after completing radiation
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FLT uptake</measure>
    <time_frame>baseline, weeks 1, 2, 3, and 4 of therapy, and 1 month post-therapy</time_frame>
    <description>Standarized uptake values of the FLT tracer signal in both the tumor volume and bone marrow volume. Changes in uptake will be assessed compared to treatment outcome as well as blood cell counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognostic outcome</measure>
    <time_frame>Post-treatment</time_frame>
    <description>Comparing change in the standardized uptake value against local and regional disease control as well as disease free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone marrow</measure>
    <time_frame>pre-treatment</time_frame>
    <description>The volume of pelvic bone that will be irradiated and the volume of active bone marrow treated as identified by the baseline FLT PET scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Weekly during treatment</time_frame>
    <description>White blood cell and platelet counts, using pretreatment blood draw as baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>post-treatment</time_frame>
    <description>Compliance with planned chemotherapy cycles (the number completed versus the number planned)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[F18]Fluorothymidine</intervention_name>
    <description>FLT PET scan 5 mCi (+/- 10%)</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>FLT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Histologically confirmed stage IB2, IIA, IIB, IIIB, and IVA squamous cell carcinoma
             of the cervix.

          -  Scheduled to receive chemo-radiation for oncologic treatment.

          -  Karnofsky of at least 60 at time of screening

          -  Life expectancy of at least 6 months.

          -  Leukocytes at least 3,000/microL

          -  absolute neutrophil count at least 1,500/microL

          -  platelets at least 100,000/microL

          -  total bilirubin at maximum 1.0 mg/dL (UIHC limit of normal)

          -  either ALT or AST less than 2.5 times the upper limit of normal

          -  creatinine less than 1.5 times the upper limit of normal

          -  non-pregnant, non-nursing, willing to use contraception

        Exclusion Criteria:

          -  oncology research protocol requiring full pelvic radiation (i.e., 4-field box
             technique) or experimental chemotherapy

          -  uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             the study requirements.

          -  subjects taking nucleoside analog medications such as those used as antiretroviral
             agents.

          -  patients who have undergone hysterectomy or will have a hysterectomy as part of their
             cancer therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Graham, Ph.D., M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah McGuire, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McGuire SM, Menda Y, Ponto LL, Gross B, Juweid M, Bayouth JE. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy. Radiother Oncol. 2011 Apr;99(1):49-54. doi: 10.1016/j.radonc.2011.01.025. Epub 2011 Mar 22.</citation>
    <PMID>21397965</PMID>
  </reference>
  <reference>
    <citation>McGuire SM, Menda Y, Boles Ponto LL, Gross B, Buatti J, Bayouth JE. 3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):888-93. doi: 10.1016/j.ijrobp.2010.12.009. Epub 2011 Feb 6. Erratum in: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):7.</citation>
    <PMID>21300484</PMID>
  </reference>
  <reference>
    <citation>Menda Y, Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010 May;37(4):433-8. doi: 10.1016/j.nucmedbio.2010.02.005.</citation>
    <PMID>20447554</PMID>
  </reference>
  <results_reference>
    <citation>McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, Smith BJ, Gross BA, Bayouth JE, Sunderland JJ, Graham MM, Buatti JM. Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):228-39. doi: 10.1016/j.ijrobp.2016.04.009. Epub 2016 Apr 19.</citation>
    <PMID>27319286</PMID>
  </results_reference>
  <results_reference>
    <citation>McGuire SM, Menda Y, Boles Ponto LL, Gross B, TenNapel M, Smith BJ, Bayouth JE. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys. 2014 Jul 8;15(4):4780. doi: 10.1120/jacmp.v15i4.4780.</citation>
    <PMID>25207403</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 5, 2016</lastchanged_date>
  <firstreceived_date>February 23, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sarah McGuire</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Radiotherapy, Intensity-Modulated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Yes, data will be shared utilizing clinicaltrials.gov results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
